SPRB Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-35.820.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$144.1MMicro cap
Wall Street coverage
$149.71median target· current $39.75 (+276.6%)5 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 4.16
- P/S (TTM)
- 49.19
- EV/EBITDA
- -0.23
Profitability & growth
- ROE (TTM)
- -148.8%
- Operating margin
- 0.0%
- Revenue growth YoY
- -75.9%
- Dividend yield
- —
- Beta
- 3.20
Last earnings
May 13, 2026 · Estimate $-6.12 · Reported $-8.94
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Spruce Biosciences, Inc. Common Stock
Company profileSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company is headquartered in Daly City, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 611 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$144.1M
Shares outstanding$2.8M
52W high$240.00
52W low$4.77
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent